Seeking Better Valuations In Emerging Markets

2020-05-29 00_55_53-Macro Photography of Tree · Free Stock PhotoIn the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on a number of metrics. For these three stocks, CLICK HERE.

Why This Cancer-Fighting Biotech With A Unique Name And Focus Belongs On Your Radar

2020-05-27 22_49_43-Pink Ribbons on Pink Surface · Free Stock PhotoThe “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus market sell-off), leads the author to recommend investors keep this company on their radars for potential buy the dip opportunities. For the biotech stock in question, CLICK HERE.

Should Biotech Stocks Come With A Warning Label At Current Levels?

2020-05-24 19_36_46-Woman in Gray Sweater Wearing Blue Framed Eyeglasses · Free Stock PhotoBiotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however, pointing to “two very important names” in the aforementioned ETF that “are starting to break down.” For more, CLICK HERE.

2 Biotech Penny Stocks With “Strong Buy” Ratings And “Sky-Scraping Upside Potential”

2020-05-18 22_33_16-Silver Liberty in God We Trust 1978 Coin · Free Stock PhotoAnticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.

2 Of The Most Promising Stocks In The Young – But Rapidly Growing – Gene Editing Space

2020-05-16 22_17_46-WindowWhen it comes to the nascent – but rapidly growing – gene editing space, the author of today’s article notes that “sector players are rapidly making progress in combating rare or difficult to treat diseases that traditional chemical based drugs simply cannot accomplish.” With the market for gene editing therapies expected to grow by over 18% annually, he highlights two of the most promising gene editing stocks for biotech investors to consider. For more, CLICK HERE.

Cannabis’ Coronavirus Disappointment

2020-05-14 23_13_35-WindowCannabis investors who bet that marijuana stocks would benefit from an increase in demand for cannabis products during the coronavirus lockdowns have largely been disappointed. As today’s article notes, even if demand for marijuana did rise with people stuck at home, “it hasn’t translated to gains for major cannabis producers.” Is more disappointment ahead from marijuana stocks? For more, CLICK HERE.

Micro-Caps, Mega Gains?

2020-05-10 19_59_56-low angle photo of flag of U.S.A photo – Free City Image on UnsplashMorgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per share or less) and huge upside potential (greater than 90% in the year to come).” For more, CLICK HERE.

3 Potential “Game-Changer” Biotech Stocks With Triple-Digit Upside Potential

2020-05-08 20_58_20-Unrecognizable chemist taking liquid with pipette from test tube in modern labor“Veteran players of the stock picking game know that biotechs are capable of delivering a win at what feels like the drop of a hat,” notes the author of today’s article, who proceeds to highlight three biotech stocks, identified by investment firm Wedbush, with the potential to be game-changers. For these three Buy-rated biotech stocks with triple-digit upside potential, CLICK HERE.